Tag: Roux-en-Y Gastric Bypass
-
Amylyx Turns GLP-1 Biology in the Opposite Direction
Avexitide met the primary endpoint in the Phase 3 LUCIDITY trial, reducing Level 2 and Level 3 hypoglycemic events by 55% versus placebo in patients with post-bariatric hypoglycemia.